{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T13:32:50.927314+00:00","company":{"ticker":"MRMD","cik":1522767,"company_name":"MARIMED INC."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"governance_change","fact_key":"f45b3484672654d8022db94293118ce17128076c","cik":1522767,"ticker":"MRMD","company_name":"MARIMED INC.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-02-26","item_codes_triggered":["5.03"],"summary_text":"Filed a Second Amended and Restated Certificate of Designation to designate the rights and preferences of the New Series B Preferred Stock."},"claim":"MARIMED INC.: Filed a Second Amended and Restated Certificate of Designation to designate the rights and preferences of the New Series B Preferred Stock (effective 2026-02-26).","evidence_excerpt":"On February 26, 2026, in connection with the Loan Restructuring Transaction, the Company filed a Second Amended and Restated Certificate of Designation to designate the rights and preferences of the New Series B Preferred Stock with the Secretary of State of Delaware.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001522767-26-000011","anchor_url":"https://secwatch.observer/filing/0001522767-26-000011#claim-f45b3484672654d8022db94293118ce17128076c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1522767/000152276726000011/0001522767-26-000011-index.htm"},{"fact_type":"debt_financing","fact_key":"59b6cd214deda0d3072f6d2687b3fabbc6baad18","cik":1522767,"ticker":"MRMD","company_name":"MARIMED INC.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"counterparty":"Navy Capital Green International, Ltd. and its affiliates","effective_date":"2026-02-24","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":"10.0% per annum","item_codes_triggered":["2.03"],"maturity_text":"March 1, 2031","principal_text":"principal amount of $6,000,000"},"claim":"MARIMED INC. incurred senior notes of principal amount of $6,000,000 with Navy Capital Green International, Ltd. and its affiliates at 10.0% per annum maturing March 1, 2031.","evidence_excerpt":"the Company issued to Navy (i) two new promissory notes in the aggregate principal amount of $8,000,000, one in the principal amount of $2,000,000, due March 1, 2028, accruing interest at a rate of 8.0% per annum (\"Note #1\") and the other in the principal amount of $6,000,000, due March 1, 2031, accruing interest at a rate of 10.0% per annum (subject to reduction to 8% if Note #1 is paid in full within six (6) months of February 24, 2026) (\"Note #2\" collectively with Note #1, the \"New Notes\")","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001522767-26-000011","anchor_url":"https://secwatch.observer/filing/0001522767-26-000011#claim-59b6cd214deda0d3072f6d2687b3fabbc6baad18","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1522767/000152276726000011/0001522767-26-000011-index.htm"},{"fact_type":"debt_financing","fact_key":"5e681f32b470f9c8d626ea0eebe3a6c061c4d541","cik":1522767,"ticker":"MRMD","company_name":"MARIMED INC.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"counterparty":"Navy Capital Green International, Ltd. and its affiliates","effective_date":"2026-02-24","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":"8.0% per annum","item_codes_triggered":["2.03"],"maturity_text":"March 1, 2028","principal_text":"aggregate principal amount of $8,000,000"},"claim":"MARIMED INC. incurred senior notes of aggregate principal amount of $8,000,000 with Navy Capital Green International, Ltd. and its affiliates at 8.0% per annum maturing March 1, 2028.","evidence_excerpt":"the Company issued to Navy (i) two new promissory notes in the aggregate principal amount of $8,000,000, one in the principal amount of $2,000,000, due March 1, 2028, accruing interest at a rate of 8.0% per annum (\"Note #1\")","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001522767-26-000011","anchor_url":"https://secwatch.observer/filing/0001522767-26-000011#claim-5e681f32b470f9c8d626ea0eebe3a6c061c4d541","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1522767/000152276726000011/0001522767-26-000011-index.htm"},{"fact_type":"material_agreement","fact_key":"28e7f019d1b1cc103c28cbccd5918446645b15c4","cik":1522767,"ticker":"MRMD","company_name":"MARIMED INC.","filed_at":"2026-03-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Restructuring and Exchange Agreement","agreement_type":"other","counterparty":"Navy Capital Green International, Ltd.","effective_date":"2026-02-24","item_codes_triggered":["1.01"],"value_text":"$8,000,000"},"claim":"MARIMED INC. entered into Restructuring and Exchange Agreement with Navy Capital Green International, Ltd. valued at $8,000,000 (effective 2026-02-24).","evidence_excerpt":"On February 24, 2026, the Company and Navy entered into a Restructuring and Exchange Agreement (the “Restructuring and Exchange Agreement”) to address and restructure the Series B Obligation","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001522767-26-000011","anchor_url":"https://secwatch.observer/filing/0001522767-26-000011#claim-28e7f019d1b1cc103c28cbccd5918446645b15c4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1522767/000152276726000011/0001522767-26-000011-index.htm"},{"fact_type":"executive_change","fact_key":"196fa48b97","cik":1522767,"ticker":"MRMD","company_name":"MARIMED INC.","filed_at":"2024-08-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-09","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Mario Pinho was appointed as Chief Financial Officer at MARIMED INC..","evidence_excerpt":"Effective August 9, 2024, MariMed Inc. (the “Company”) appointed Mario Pinho as the Company's Chief Financial Officer to replace Jon Levine, the Company's Interim Chief Financial Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001522767-24-000069","anchor_url":"https://secwatch.observer/filing/0001522767-24-000069#claim-196fa48b97","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1522767/000152276724000069/0001522767-24-000069-index.htm"},{"fact_type":"earnings_release","fact_key":"96103019460340e8c03e50c040794023fa995bc6","cik":1522767,"ticker":"MRMD","company_name":"MARIMED INC.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$ (1.3)","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$ 37.9"},"claim":"MARIMED INC. reported the first quarter ended March 31, 2024 results: revenue $ 37.9, net income $ (1.3).","evidence_excerpt":"1 The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts): Three months ended March 31, 2024 2023 Revenue $ 37.9 $ 34.4 GAAP Gross margin 43 % 45 % Non-GAAP Gross margin 44 % 46 % GAAP Net loss $ (1.3) $ (0.7) Non-GAAP Net (loss) income $ (0.6) $ 0.3 Non-GAAP Adjusted EBITDA $ 4.7 $ 7.1","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001522767-24-000040","anchor_url":"https://secwatch.observer/filing/0001522767-24-000040#claim-96103019460340e8c03e50c040794023fa995bc6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1522767/000152276724000040/0001522767-24-000040-index.htm"},{"fact_type":"earnings_release","fact_key":"ef5f6bd0bb26ef48cfbb93ac03d0b1581286ddbe","cik":1522767,"ticker":"MRMD","company_name":"MARIMED INC.","filed_at":"2024-03-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and year ended December 31, 2023","report_date":"2024-03-06","result_type":"reported_results","revenue_text":null},"claim":"MARIMED INC. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 6, 2024, MariMed Inc. (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, announcing its financial results for the three months and year ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001522767-24-000005","anchor_url":"https://secwatch.observer/filing/0001522767-24-000005#claim-ef5f6bd0bb26ef48cfbb93ac03d0b1581286ddbe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1522767/000152276724000005/0001522767-24-000005-index.htm"}]}